CORONA Remedies has successfully commenced the additional commercial production of tablets/capsules at the Bhayla manufacturing facility (Facility) of the company. As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%. The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the Facility.
The additional commercial production will add a significant milestone in the company’s strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility. The commercialized additional capacity is entirely being funded through internal accruals.
Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: